Executive will be in charge of medical device business in North America.
New hire will lead company's goal to become leading independent evaluator for industry.
The lawsuit specifically targets three top executives.
After U.S. recall, company revises labeling to reflect possible risks.
Company is focused on upping the visibility of its neuro-oncological device.
In an interview, President Obama made it clear he opposes efforts to delay or repeal the tax.
The company snagged DePuy Spine's departing worldwide president.
Growing chorus of lawmakers from both parties push for a postponement.
Company is pursuing gold standard technology to prevent pulmonary embolism.
Single-loop design updates the company's three-looped device.
Company continues push to grow medical manufacturing.
New hire initially joined the company as an adviser to the board.
Industry still pushes for repeal.
As previous executive officer steps down, the search begins for a permanent replacement.
The facility consolidates Aptiv and its N.C. subsidiaries in one location.
Company gains access to wider geographic markets as well as dialysis products to add to its portfolio.
Both companies will benefit from their expanded position in the contract manufacturing marketplace.
Spectralytics will become part of the newly minted Cretex Medical group of companies.
LifeScience Alley connects medtech companies with the FDA in a new partnership effort.
The expansion includes assembly space as well.
The new location will focus on laser technologies among other functions.
The purchase affords Volcano access to Crux's inferior vena cava filter system.
Some repairs show 100 percent rate of recovery, according to journal report.
Company also approves massive share buyback program.
The agency moves forward with obligations set forth by recent legislation, while some remain skeptical.
Healthpoint will bolster S&N's wound management business.
The system is designed to be a bridge to heart transplant.
A full acquisition is planned.
The company enters the finished device business.
Together the companies hope to create a robust AED business.
The device is intended to eliminate the need for bypass during heart surgery.
The company aims to expand selling and marketing capacity north of the U.S. border.
A GE company, Thomas Medical is Merit's second recent acquisition.
Company hopes to mitigate scrutiny into PCI procedures with Sync-Rxâ€™s technology.
Company highlights machine's extremely thin slicing capabilities.
Analysts wary of the high price paid for the Chinese company.
The system delivers localized drugs, particularly useful for chemotherapy treatment.
Though unexpected, departure is on good terms.
Money will fund commercialization and next-generation technology.
Technology is the result of 20 years of academic research.
Countries use innovative measures to promote their biotech/medical device sectors.
Futuristic medical products dazzle attendees at trade show.
New ACC wire builds on existing company technology.
Company moves forward with plan to be player in medical imaging market.
The appointments are part of a management realignment effort.
Winner chosen from nine mobile health applications.
The drug-eluting stent delivers paclitaxel to treatment sites.
Firms at Medica and Compamed tout preparedness on the non-DEHP front.
Medtech industry urges lawmakers to nix innovation-killing levy.
Company claims its system helps to "remove any doubt" from the decontamination process.
New copolyester from Eastman is used for Hopf's latest line of stopcocks and Y connectors.
As system technology evolves, possible applications become numerous and varied.
Technology combines special biosensor materials with advanced electronics.
New low cost POC analyzers make their debut at Medica.
Biopsy punch is designed to remove risk of cross contamination.
Company releases sensor that can detect heart rate, respiration through chair cushion.
Firm shows off its technology in real-time to assess the collective health of show-goers.
Latest iteration imports various features from earlier device.
Medical 3-D recorder, 3-D camera among innovation debuting at show.
New device launched during World COPD Day.
The firm's technology is used to protect high-speed rotary drive units in medtech.
Antimicrobial products are highlighted at this year's show.
With an increase in customer quality expectations, the company anticipates growth.
Organizers expect more than 4,500 exhibitors from 64 countries to attend event.
Company is broadening its reach in European markets.
Company is billing new device as iPad of microscopy.
The buy strengthens Steris' position in what is currently a fragmented market.
The location is expected to be fully operational by March.
Launch made during Compamed trade fair in Germany.
New name reflects move beyond simple healthcare adhesives.
A PR executive shares tips about how to harness the unique benefits of B-to-B trade shows.
Molded and thermo-formable, medical-grade foams among products featured.
Annual trade fairs in Germany attract global audience.
UL will fold Wiklund Research & Design into its life and health business.
The Sapien valve can now be inserted through the ribcage.
Helix gains footholds in key U.S. medtech clusters.
After three successful fiscal quarters, CEO hopes new addition will help maintain continued performance.
The result is the newly named Cretex Medical.
The new space is four times the size of the old location.
The facility provides services to European and North American customers.
India's currency has lost more than a quarter of its value since the summer of 2011.
The module can be used with most picture archiving and communication systems.
Omar Ishrak spoke to an audience at Cleveland Clinic's Medical Innovations Summit 2012.
Consultant provides a basic primer for new medical device establishment registrations.
Neomed will be added to Bard company Davol.
The facility will be dedicated to medical device materials, components and R&D.
Innovation depends on protecting intellectual property.
The device is designed to reduce accidental needlesticks.
Lobo plans to focus on efficacy rather than product innovation.
Approved in the E.U. already, the trial is one more step toward U.S. approval.
Senate findings suggest Medtronic manipulated Infuse bone graft data.
Venture intended to help physicians better control vascular images.
FDA not supportive of reused cardiac devices in the United States.
Repurchase plan is Cadence's vote of confidence in its own future.
Stent has enjoyed success in Europe.
Company distributes device for Chinese firm Lepu Medical Technology.
The Beehive State shows significant medical device growth.
Vascular Nanotransfer Technologies looks to create "gold standard" technology.
Experts met at the National Institute of Standards and Technology to discuss the issue and what steps should be taken.
Gov. Patrick continues push for medtech in the Bay State.
The purchase strengthens Helix's product life cycle management.
CEO would not cite specifics, but disclosed the expectation in the interest of transparency.
This is a natural move for Stryker, which continues to bolster its stake in the fast-growing neuro market.
The problem has been seen before in the west, possibly because stent procedures are so profitable.
The announcement comes less than a month after another purchase.
Judge rules company does not have to pay $82.6 million previously ordered.
Former CEO leaves after a decade.
Company rebranding itself to highlight blood-based test.
AorTech accuses St. Jude of an unspecified contract breach.
Cook Medical's Zilver PTX stent not yet available in the United States.
Company under the guidance of an interim CFO since last year.
Company joins Stryker, Medtronic, and others in downsizing.
Interim CFO has been appointed in the meantime.
The agency cites improper procedures by the plaintiffs.
The program tackles IP resulting from industry funding.
The addition of Coeur will expand ITW's product line.
Vortex's products will be folded into AndioDynamics' peripheral vascular portfolio.
The medical device giant seeks to expand in the electrophysiology market.
The company received an IDE from the FDA for the device.
Second Sight's device treats retinitis pigmentosa, a rare disease that can cause blindness.
The reports will provide basic information on current diagnostics innovation.
The companies hope to streamline their capabilities for clients.
AdvaMed panel provides insight on the issue.
"Licensed to Cure" enables companies to master relationships between product innovation, quality assurance and regulatory compliance.
Predicted completion of expansion is April 2013.
Latest Ernst & Young report indicates solid performance in 2011.
AdvaMed panel stressed communication and preparation as key to navigating compliance requirements.
At AdvaMed 2012, paralyzed patient walks aided by company's mobility system.
The health IT panel at AdvaMed 2012 featured medtech representatives and patient advocates.
New hire is an expert in regulatory affairs and compliance.
The program is the first of its kind in the United States.
The anticipated U.S. release is fall 2013.
Speakers at the device association’s annual conference examine this year’s presidential contest.
CEO says the acquisition is part of Medtronic's goal of globalization.
The device is the next-generation version of Clearbridge's ClearCell System.
The agency's OK comes following a warning letter earlier in the year.
The newly created position is meant to drive the development of Utah's life sciences sector.
The new location will provide a nexus for China and other regional clients.
The medical device giant is adding BridgePoint to its Interventional Cardiology Division.
The two companies are focused on the treatment of epilepsy.
Device now can be used in patients 65 and older.
The new hire will focus heavily on R&D for pharmaceutical and medical device customers.
The trade fairs in Germany provide a forum for players from all corners of the medical technology industry to come together.
The needles are targeted toward diabetes patients who fear needles due to pain or discomfort.
The system is geared toward women with dense breast tissue.
The company manufactures podiatric devices.
The devices are available in both the U.S. and the E.U.
Iris will join Danaher's Beckman Coulter diagnostics business.
Latest delay could cost the company NYSE listing.
Officials claim the space of interoperability needs to be developed.
The New Hampshire facility is hoped to provide 25 new jobs.
Rep. Paulsen and industry advocates believe government is unprepared for the implementation of the tax.
The facility is the company’s first in Latin America.
The system is relatively affordable, a big attraction for emerging markets.
New hire brings experience in product innovation.
Citing the medical device excise tax, the company looks outside the United States for new business opportunities.
Research company details how the market share is divided globally.
The new version of the Impella is doubly powerful, company claims.
Entries may still be submitted until the end of October.
Researchers believe Intact Vascular’s new technology will not best existing technology.
The CE Mark approves the system to treat chronic pain and patients who need MRIs.
This report is part of a slew of steps the FDA is taking to keep the promises of MDUFA.
The device is being updated, and the new version will be re-submitted for approval.
The device received European approval earlier this year.
Restore Medical Solutions was one of the first companies to participate in the accelerated device development program.
The cover is intended specifically for obese patients.
The news comes soon after the release of a new Arrow catheter earlier this month.
The company received the CE Mark a year after it received FDA clearance.
The investment will go toward the development of a blood flow monitoring device.
Specialty Manufacturing’s expansion more than doubles its plant size.
The new Canton location will manufacture polymer tubing.
The two companies will join forces on a self-injection drug delivery system.
The company hopes to be one of the few welding companies to achieve the medical device ISO standard.
The company consolidates product divisions and shuffles its executive leadership.
The company has received FDA clearance for the device.
Company says trial results best Medtronic’s Endeavor stent.
The company’s Costa Rica plant is under scrutiny by the FDA.
The investment is in line with China’s current focus on biotechnology.
The company is beginning the process to release the device in the United States.
Sirigen is a Nobel Prize winning polymer technology company.
Getinge hopes to bring the Therapeutic Support Systems business to its European markets.
The valve is a new version of the company’s older sterilization product.
The company hopes to establish Jarvik device’s superiority to others on the market.
Siemens will bolster its ultrasound business with the purchase.
Millennium Research Group cites market saturation for the sluggish growth prediction.
Zoll’s wearable defibrillator will now benefit from Inovise’s acoustic cardiography technology.
The graft is designed to facilitate sutureless anastomosis, among other applications.
The new hire joins Toshiba from Philips Healthcare.
GE and Orbimed join to invest in the oxygen monitoring device company.
The new two new microcoil systems are available in the United States and Europe.
Helix will acquire half of all company shares by next year.
The company will develop a biothreat detection instrument.
The agency hopes to further speed up review times with this guidance.
The results are good: The company can replicate lowered blood pressure both in office and over 24-hour monitoring.
The lancet comes in sizes for newborns and preemies.
The company promotes COO to CEO position.
CEO has experience in both medical devices and contract manufacturing.
The purchase will beef up Teleflex’s anesthesia business.
The system delivers baclofen for the treatment of spasticity.
The device is intended to treat iliac artery disease.
The acquisition prompts a revision of Masimo’s financial predictions for 2012.
The suture has been in use since 2004.
New hire brings 15 years experience in sales and marketing.
Kevin King replaces Bill Willis on the board.
The SFDA announced the new procedure on June 18.
The device is a new addition to the SuperCross product line.
The system is designed to help physicians monitor oxygen levels more quickly.
Studies show elevated exposure could have emasculating effects on male patients.
Semprus BioSciences division gains EU clearance for catheter technology.
The company’s Mexico facility has been awarded an ISO 13485 certification.
The device can be integrated with drugs and pharmaceuticals.
The company has been awarded the ISO 13485 certification for electroporation devices.
The device treats benign prostatic hyperplasia.
NSF's list of services will be complemented by what Becker & Associates brings to the table.
The money will fund an expansion of the university’s Medical Devices Center.
ImageIQ will provide imaging analytics to Histogenics.
Fresenius insists it still has buying power for a takeover of Rhoen-Klinikum.
The company highlights the cost effectiveness of its new products.
The Frost & Sullivan Award recognizes innovation among other achievements.
CEO says company will be able to match human tissue closer than ever before.
The companies hope to get medical devices to market sooner by joining forces.
The company is questioned for a possible delay in public disclosure.
STERIS CEO dubs the deal the company’s “most significant” in a long time.
The deal is anticipated to close by the third quarter of 2012.
Senator puts pressure on FDA to explain itself.
New owner pledges growth.
The conference will focus on local companies and connect industry players.
BD will gain a line of anti-needlestick devices.
The new R&D center will focus on the cardiovascular and neuromodulation markets.
Winning Apps will present at Medica 2012.
The amendments have supporters and dissidents from all sides.
Internal funding will go toward an annuplasty device, while external funds fuel spin-off.
News of the deal has caused dismay among investors.
The respiratory device company will introduce a new product to the Brazilian market.
The bill’s approval has been praised for its rare bipartisan effort.
The company attracts Medtronic executive to fill the role.
The stent joins the company’s Evolution line of stents.
The neurological device is already approved to treat a number of other disorders.
Device identification is mandated by the recently passed user fee legislation.
The system will be used in prostatectomies.
The device is under review for the CE Mark.
The most controversial aspect of the bill, the individual mandate, was also upheld.
The device is designed to help surgeons identify all cancerous tissue during lumpectomies.
The passage of the legislation praised as a rare example of bipartisan American politics.
The line will be introducued via subsidiary Symmetry Surgical
The Durata lead is now under fire, but the company claims the lead failure was caused by external factors.
New facility is just a few miles from the company’s orthopedic design location in Warsaw, Ind.
The Valiant Mona LSA System treats descending thoracic aortic aneurysms
Darlene Deptula-Hicks has a strong background in medical device finance.
The V-Loc now can be paired with the company’s other suturing devices.
The company developed the products under advisement from a panel of nursing professionals.
The company taps former JNJ bigwig to head up its Chinese operations.
The Dominican Republic manufacturing plant is producing surgical staples but will expand soon.
New hire most recently was a Covidien executive.
Viewpoints and progress on repealing the medical device excise tax.
Pumps manufactured after November 2010 are exempt.
The Amplatzer vascular plug offers an alternative to traditional embolic coils.
The manufacturing facility will cater specifically to the Indian market, but has the flexibility to expand for other global markets as well.
Fazio and Healy bring extensive cardiac experience to the table.
Viveve to introduce a device for women post-childbirth.
Study finds defibrillators are located too far away from victims.
Rate of use has generally increased, especially for orthopedics.
John Schulte is sentenced to 12 months of probation, fined $5,000.
With some slick maneuvers, the company also manages to minimize its U.S. tax hit.
Deal is expected to close by June 30.
Equanox measures oxygen saturation in both brain and body tissue.
The company has been strategically buying and selling with plans to establish presence in key global markets.
The company voluntarily decided to achieve certification to assure clients it has quality standards in place.
The move is unexpected, as the company only purchased the plant three years ago.
The young company has Wicker to thank for significant funding it received for its dry eye devices.
Richard Meelia occupies a newly created seat on the board of directors.
Sizes will benefit taller, larger patients.
William Knight steps down as Charles Wagner takes his place.
Tension rises as the medtech industry inches closer to its goal of a total repeal of the tax.
As the company recovers from bankruptcy, Starkman has a particular set of challenges ahead.
Similar measure would be unlikely to pass in the Senate.
The new catheter features multiple ports, whereas the previous version had only one.
The company appoints new members, accessing expertise to help its products on the market.
The system treats abdominal aortic aneurysms, and has been available in Europe since December.
The company continues to show active interest in growing its South American presence.
The company also will invest in a new U.S. facility.
The congressmen represent the bipartisan support the device tax repeal has garnered.
Kevin Madden and Karen Finney use their expertise in political strategy to advise MDMA members how to move forward.
Legislation is similar to Senate bill that passed last week.
The company sets its sights on global expansion.
The Resolute DES is being studied for its effectiveness in patients with both coronary heart disease and diabetes.
Incubator doubles as an infant warmer.
Company simulates hospital setting to introduce and showcase devices.
ETView will begin marketing the devices in the United States immediately.
The financing will fund next-generation drug-delivery products.
Efforts continue to repeal the 2.3 percent device excise tax set to come to fruition next year.
CEO Vincent A. Forlenza will take on his new responsibilities in July.
The subsidiary of Dixie Medical provides medical equipment repair services.
The foundation has granted almost half a million dollars to Partners in Health to work against NCDs in Rwanda.
The Navigator was designed by clinicians, and comes with a range of features.
Gregory Andrulonis is a long-time employee of the firm.
This is a step toward reimbursement for the devices.
A statistical snapshot of Latin America's largest healthcare conference.
Organizers add Digital Health segment to event to address growing mobile health market.
Frisco, Texas, has a lot to offer the growing company.
The company intends for the system to be used with Cesium-131, which it exclusively manufactures.
George Bourne joins AngioDynamics after its acquisition of Navilyst.
Valued at $2.2 billion, the deal is expected to close within two months.
IV Clear uses a more skin-friendly silicone adhesive along with gold-standard antimicrobial agents.
The company refinances senior and subordinated debt obligations and appoints new chairman of the board.
The device has the potential to improve the treatment of Barrett’s esophagus.
The device is designed to monitor neuromuscular blocking agents, but has other uses as well.
An idea two years in the making, the United States will be the first country to do so.
PKU hopes to benefit from Devon sending more companies their way.
GBI and Stericycle present data.
St. Jude will release further data later this year.
The system uses ablation technology to reduce blood pressure.
Industry players aren't easing off on the pressure to repeal the tax.
Joe D'Antonio brings years of sales experience with him.
The stent is used to treat peripheral vascular lesions in arteries above the knee.
The companies look forward to an "ongoing relationship."
After doing business in the country for 25 years, JNJ has purchased Bioseal Biotech.
Lee Brody will be focusing on company's new product.
As yet unknown what type of jobs they will be.
The deal is valued at $108 million.
Calum Cunningham has been with the company for three years.
Maria Sainz comes with an impressive resume.
Toshiba expands its Aquilion line.
The company has announced it will acquire Hemerus Medical.
Seventeen companies commit to reducing waste and preserving the environment.
The company continues its trail of Israeli acquisitions.
Charles Davidson's relationship with the company goes back three years.
After a year, Gen-Probe finds a buyer.
Hudson headquarters not spacious enough.
Purchase will expand the company's cytometry business.
The anti-hacking device is still in its beginning stages.
Company adds to manufacturing footprint in the United States and opens new facility in Costa Rica.
The HSA revises its brand new device registration rules.
First quarter analysis shows earning are up slightly from last year.
JNJ expects the merger to be complete in Q2.
David Dvorak discusses association's three-year advocacy plan.
SynGen gets $5 million to fuel stem cell harvesting devices.
CEO steps down as the company moves ahead in the weight loss sector.
The company progresses in the heart sector despite recent lead wire controversy.
Complexities of law and the wording of his claim prohibit paraplegic Richard Stengel from suing.
Kenneth Marshall joins Aerocrine from Ikaria.
Nurses anticipated to benefit from the system's ease of use.
The surgical navigation system will pair with Neurologica's BodyTom CT scanner
The Ellipse ICD receives CE Mark approval.
The company claims Powerease reduces fatigue in surgeons.
The ISPAB warns about danger, while researchers get closer to preventing the problem.
Cofounder steps down from the post after fourteen years.
The study will take place in 55 U.S. cities, and is already underway in Europe.
The biopolymer scaffolding device is hoped to be the first effective treatment for spine-related paralysis.
The system should detect cancer better and earlier, company claims.
In another shuffle, Philips faces some challenges in the face of a drop in demand for its healthcare products.
Thrower and Steuben bring experience from other industry leaders.
Donald Casey will assume his post on April 16th.
The sheath will be used to position catheters within the heart.
Wounded warriors look ahead to possible improved rates of limb salvaging.
The device utilizes suction pressure to accelerate healing.
The CRT-D devices will puportedly reduce mortality rates in early-stage heart failure risk patients.
Accusations fly as the company struggles against bad PR and falling share prices.
Local customers will enjoy easier access to company products.
All three devices treat end stage renal disease.
The FDA currently is reviewing the devices for the U.S. market.
Randall Barko comes with 30 years experience in the business.
The acquisition will bring breathing-assistance devices to Covidien.
Though not a recall, the letter warns physicians to be vigilant in their monitoring of affected implanted cardio devices.
Thoratec claims it is more of a correction than a recall.
85 year old patient experienced chest pain relief.
The report finds increased review times.
Move comes amidst Johnson and Johnson's negotiation with European antitrust authorities.
Merger expected to be finalized within three months.
Company denies any wrongdoing.
The combination product is made up of a gel that works together with a catheter.
Acquisition valued at $14.5 million.
The company doesn't specify how much it hopes to sell for at the IPO.
The system will be used to position mesh over hernias.
Richard Altieri is a veteran of the medical device financial arena.
CoZmonitor system no longer has any compatible testing strips on the market.
Will be replaced by current CEO, John McDermott.
Symmetry's acquired technology gets a new look.
Company says death count is less than study shows.
Data continues to focus on effects to R&D and jobs.
Cathether system is designed for long-term vascular access.
Agreement broadens markets for both firms, gives AngioDynamics first shot at purchase.
Technology was acquired through Codman & Shurtleff purchase.
Guidewire system helps to determine severity of artery blockage.
Penalty includes DPA and fine.
New exec brings experience in high-tech manufacturing.
Plans call for doubling existing manufacturing space.
Pluromed will become part of Sanofi Biosurgery.
The price tag was 10 times the acquisition target's annual sales.
The OMB gives the pact its OK.
Lawmakers want a law to ensure that medical devices are easy to track.
Public Citizen claims risks of product outweigh its benefits.
Firm opens new office in Germany.
Organization is positioning itself prior to April launch date.
Zimmer's CEO replaces head of Abbott Medical Optics
The $8 million deal is expected to be accretive to Span-America's fiscal 2012 earnings.
Company has been aggressively growing its medical device business.
Deal is expected to close in the second quarter.
The transfer will eliminate jobs but executives are not providing specific numbers just yet.
New semiconductor division created as a result of purchase.
New structure better positions company to seize opportunities for medtech growth, leadership says.
Company hopes to breathe new life into its CRM business.
Firm makes devices used in liver surgery.
Company says significant clinical trial results aided product's regulatory OK.
New Minnesota-based group combines industry, government and academia.
System now approved in all major markets worldwide.
Company, CEO pay penalties for distributing unapproved medical devices.
CMS is expected to issue its final NCD within approximately 60 days.
Acquisition supplies hardware and software for X-ray workstations.
Company hopes to have its Low Glucose Suspend feature approved with its Paradigm system for use in the United States.
Company blames supplier for faulty component.
Sale is part of continued focus on medical technology markets.
DARPA contract calls for flexible, highly adaptable device.
BioOhio workforce development and Sinclair Community College partnership highlighted.
Former executives charged with accounting fraud.
Acquisition expands Orchid's contract manufacturing capabilities.
Company is prepared to pay $43 million to close investigation into bone-growth lawsuit.
Company promotes medical device and diagnostic unit chief.
Program aims to provide seed funding and FDA savvy for startup firms.
Firm specializes in neuroscience market.
Former CEO will stay on board for a transition period.
Company is gearing up for FDA clearance next year.
Agency deems modified guidewires 'adulterated.'
Republican encourages 'further dialogue' to explore alternatives.
Company pays $15 million fine, pleads to one misdemeanor charge.
Creates new website to inform patients about tools available to minimize infection risk.
GPS-like HeartNavigator creates a three-dimensional image.
Most products from Oridion Systems back on track for U.S. shipment.
French breast implant uproar highlights need for regulatory overhaul, advocates argue.
Partnership leverages each firm's talents to provide a complete solution of medical device customers.
Departure is immediate and CFO takes the reins temporarily.
Three former sales representatives named in lawsuit.
Purchase expected to add $60 million in new sales.
Name change is the result of last summer's Medisize buyout.
Company paying $22 million to end investigation over suspected bribing of Greek healthcare providers.
Ostial founded by family with innovative product development track record.
Company also pursuing strategic alternatives for its Therapeutic Support Systems business.
Industy has agreed to doubled fees for better review times and other improvements..
Clearance opens international markets for the firm.
New group within association to tackle device-specific issues, grow business in the state.
Agreement involves central venous catheter sets.
Deal expected to double AndioDynamics share of the vascular access market.
Revenue grew 1 percent in constant currency sales in FY2011.
System includes right ventricular lead and connector used with ICDs.
Cuts mostly come from stent-making business.
Cost of hip recall significantly impacts the quarter.
A new report suggests the sector is slowing, but could be buoyed by new biotech offerings.
Latest hire will manage 4,000 global employees.
Results expected in two years.
Facility to produce medical devices for detecting and treating lung cancer and pulmonary disease.
Tubes will be used for single-use pharmaceutical kits.
Letter sent to GOP leaders said info is critical to user-fee reauthorization talks.
Analyzed data to be available soon.
Company says device remains safe for other indications.
New approval includes treatment of aortic tears or ruptures.
Company gains CE mark for second generation of Endurant stent; U.S. OK expected this year.
New surgical instrumentation and refined surgical techniques aid ACL repair.
Company says it is the first to achieve new federal standard.
Purchase extents Terumo's access device business.
Government attempting to boost device sector by separating it from drugs.
Ortho giant will add Synvasive's product line to its recon division.
Pays $30 million for American contract manufacturer.
Study validates Smith & Nephew knee replacement technology.
Acquires majority stakes in two Chinese firms.
Association takes on drug and device regulatory issues.
Group within association reorganizes efforts on behalf of its small to midsize members.
Purchase boosts medical device business opportunities for RTI.
Agency wants more safety data when used to treat incontinence.
Ortho company will use funds to increase new product R&D.
Inter-company transfer pricing of technology license agreements is at issue.
Deal is worth nearly $1 billion.
Predicted growth in cardiovascular business means more space is required.
Class action filing accuses Cooper Companies of artificially inflating stock.
Ex-vice president receives eight-month term over illegal clinical trials.